drugset / Trial / NCT02401035

PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects

NCT02401035

Phase 4 Terminated 19 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the pharmacokinetics (PK) and safety of intravenous (IV) pantoprazole in patients 1 to 16 years old who are candidates for acid suppression therapy.

Timeline

Start
2017-05-09
Primary completion
2021-06-18
Completion
2021-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Pantoprazole Other / unclassified 10 mg Intravenous
Subject Pantoprazole Other / unclassified 20 mg Intravenous
Subject Pantoprazole Other / unclassified 40 mg Intravenous